Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05905250 · ClinicalTrials.gov registry record · NA
mHealth for Young Adult Cancer Survivors
A NA study, sponsored by George Washington University.
- Completed
- Registry status
- NA
- Development phase
- 155
- Enrollment target
NCT05905250: Completed NA study, sponsored by George Washington University.
NCT05905250 is a NA study that has completed, run by George Washington University. The registered enrollment target is 155 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05905250, a NA study, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
Study Summary
We aim to refine and pilot test an 8-week phone- and app-based intervention to promote hope, and thereby mitigate life disruption caused by cancer diagnosis and treatment, among young adults (YAs); our proposal involves (Aim 1) formative research among YA survivors and healthcare providers; and (Aim 2) an randomized controlled trial (RCT) of the intervention vs. attention control among 150 YA cancer survivors. The proposed research is innovative in its use of: 1) a novel intervention target - hope - as a mechanism for addressing goal-disruption and quality of life (QOL) among YA survivors; and 2) novel mHealth components and population-based recruitment strategy (via social media) that are particularly relevant to YA survivors and those with potentially limited access to healthcare. This proposal has potential high impact due to the number of YA cancer survivors for whom the intervention may be relevant, the intervention's potential utility in enhancing hope and QOL among YAs, and its reach/scalability.
Primary Outcome
Number of Participants with Retention at End of Treatment
Interventions
- BEHAVIORAL Health education
- BEHAVIORAL an empirically supported protocol, further refined with evidence-based strategies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2025-02-28 |
| Phase | NA |
What the finished NCT05905250 record still lists
NCT05905250 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Health education is the first listed.
NCT05905250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05905250 about?
NCT05905250 is a clinical study titled "mHealth for Young Adult Cancer Survivors". We aim to refine and pilot test an 8-week phone- and app-based intervention to promote hope, and thereby mitigate life disruption caused by cancer diagnosis and treatment, among young adults (YAs); our proposal involves (Aim 1) formative research among YA survivors and healthcare providers; and (Aim...
What is the current status of trial NCT05905250?
This trial is currently completed. It is a NA study. The enrollment target is 155 participants. The study started on 2024-03-15. Estimated completion is 2025-02-28.
What interventions are being tested in trial NCT05905250?
The interventions under investigation include: Health education (BEHAVIORAL), an empirically supported protocol, further refined with evidence-based strategies (BEHAVIORAL).
Who is sponsoring clinical trial NCT05905250?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05905250's enrollment target sits among peer trials
155 656th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI